Pular para o conteúdo
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Idioma
Todos os campos
Título
Autor
Assunto
Número de Chamada
ISBN/ISSN
Tag
Buscar
Avançada
Traficet-EN (CCX282-B), an ora...
Citar
Enviar por SMS
Enviar por e-mail
Imprimir
Exportar registro
Exportar para RefWorks
Exportar para EndNoteWeb
Exportar para EndNote
Link permanente
Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
Detalhes bibliográficos
Principais autores:
Bekker, P
,
Velde, A
,
Pronk, I
,
Keshav, S
,
Hommes, D
,
Hanauer, S
,
Ungashe, S
,
Zheng, W
,
Wright, K
,
Schall, T
Formato:
Conference item
Publicado em:
2007
Itens
Descrição
Registros relacionados
Registro fonte
Registros relacionados
Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
por: Keshav, S, et al.
Publicado em: (2007)
PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
por: Bekker, P, et al.
Publicado em: (2009)
PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
por: Keshav, S, et al.
Publicado em: (2009)
PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease
por: Keshav, S, et al.
Publicado em: (2007)
Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial
por: Bekker, P, et al.
Publicado em: (2008)